PMID- 32176827 OWN - NLM STAT- MEDLINE DCOM- 20210810 LR - 20221207 IS - 1365-2710 (Electronic) IS - 0269-4727 (Linking) VI - 45 IP - 5 DP - 2020 Oct TI - Predictive factors associated with glycaemic response to exenatide in Chinese patients with type 2 diabetes mellitus. PG - 1050-1057 LID - 10.1111/jcpt.13134 [doi] AB - WHAT IS KNOWN AND OBJECTIVE: Exenatide is widely used in the treatment of type 2 diabetes mellitus (T2DM) because of its established effect on lowering glucose and promotion of weight loss. However, therapeutic response to exenatide varies considerably among patients with T2DM. The purpose of this study was to determine which variables can predict the response to exenatide and to individualize specific therapies for patients with T2DM who need treatment with exenatide. METHODS: This is a retrospective cohort study of patients with T2DM who were treated with exenatide twice daily as a part of their diabetes care for at least 12 months. Patients were categorized into two cohorts based on glycaemic response to exenatide use: responders and non-responders. RESULTS AND DISCUSSION: One hundred forty-eight patients met the inclusion criteria; among them, 92 responded with an HbA1C reduction >/=1.0% from baseline HbA1C and 56 did not respond to exenatide after 6 months of exenatide treatment. Binary logistic regression analysis revealed that baseline HbA1C and duration of diabetes were identified as predictors of HbA1C reduction >/=1% at 6 months (P < .05). Linear regression analysis further identified that patients with a higher baseline HbA1C (>/=7.4%) and shorter duration of diabetes (15.0 years) were not likely to respond to exenatide. WHAT IS NEW AND CONCLUSION: Our data indicate that T2DM patients with a higher baseline HbA1C and a shorter duration of diabetes are more likely to have a glycaemic response to exenatide than those with a lower baseline HbA1C and a longer duration of diabetes. The identification of predictors of therapeutic response to exenatide can provide clinically useful information for characterizing the patients who could receive the greatest benefit from exenatide. CI - (c) 2020 John Wiley & Sons Ltd. FAU - Wang, Tao AU - Wang T AUID- ORCID: 0000-0003-0465-3167 AD - Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China. AD - Department of Pharmacy, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. FAU - Zhang, Fan AU - Zhang F AD - Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China. FAU - Wang, Xiaotong AU - Wang X AD - Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China. FAU - Li, Xizhi AU - Li X AD - Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China. FAU - Ling, Hongwei AU - Ling H AD - Department of Endocrinology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. FAU - Lv, Dongmei AU - Lv D AD - Department of Pharmacy, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. FAU - Yin, Xiaoxing AU - Yin X AD - Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China. FAU - Lu, Qian AU - Lu Q AD - Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China. LA - eng PT - Journal Article DEP - 20200316 PL - England TA - J Clin Pharm Ther JT - Journal of clinical pharmacy and therapeutics JID - 8704308 RN - 0 (Blood Glucose) RN - 0 (Glycated Hemoglobin A) RN - 0 (Hypoglycemic Agents) RN - 0 (hemoglobin A1c protein, human) RN - 9P1872D4OL (Exenatide) SB - IM MH - Adult MH - Asian People MH - Blood Glucose/*drug effects MH - Cohort Studies MH - Diabetes Mellitus, Type 2/*drug therapy MH - Exenatide/*pharmacology MH - Female MH - Glycated Hemoglobin/metabolism MH - Humans MH - Hypoglycemic Agents/*pharmacology MH - Male MH - Middle Aged MH - Retrospective Studies MH - Time Factors MH - Treatment Outcome OTO - NOTNLM OT - exenatide OT - glycaemic response OT - haemoglobin A1C OT - predictive factor OT - type 2 diabetes EDAT- 2020/03/17 06:00 MHDA- 2021/08/11 06:00 CRDT- 2020/03/17 06:00 PHST- 2019/12/03 00:00 [received] PHST- 2020/02/06 00:00 [revised] PHST- 2020/02/27 00:00 [accepted] PHST- 2020/03/17 06:00 [pubmed] PHST- 2021/08/11 06:00 [medline] PHST- 2020/03/17 06:00 [entrez] AID - 10.1111/jcpt.13134 [doi] PST - ppublish SO - J Clin Pharm Ther. 2020 Oct;45(5):1050-1057. doi: 10.1111/jcpt.13134. Epub 2020 Mar 16.